Table 1.
Table representing the clinical information.
| Sex | Age of onset (years) | Age at death (years) | Braak stage | APOE | PMI (h) | |
|---|---|---|---|---|---|---|
| AβPParc1 | F | 53 | 66 | VI | 3/3 | >30 |
| AβPParc2 | M | 61 | 64 | VI | 3/3 | 12 |
| PSEN1ΔE9 | F | 51 | 66 | N/A | 3/3 | 5 |
| AD1 | F | 59 | VI | 3/3 | 4 | |
| AD2 | F | 73 | V | 3/3 | 1.5 | |
| AD3 | F | 59 | V | 3/4 | 10 | |
| Control 1 | M | 62 | I | 3/3 | 7 | |
| Control 2 | F | 71 | I | 3/2 | 7 | |
| Control 3 | M | 79 | II | 3/3 | 9 |
Demographic information for patients with autosomal-dominant Alzheimer’s disease, patients with sporadic Alzheimer’s disease and normal controls.
AD Alzheimer’s disease, APOE apolipoprotein E, AβPParc Arctic amyloid-β protein precursor mutation, F female, M male, N/A not applicable, PMI postmortem interval, PSEN1ΔE9 PS1 exon 9 deletion.